@tanyabondar.bsky.social
Reposted
Attending the #IMS25 Regulatory Session?
Check out this review article on how MRD received FDA approval as an early endpoint for myeloma and what this means for accelerated drug approval:
buff.ly/jCeKyZp
Check out this review article on how MRD received FDA approval as an early endpoint for myeloma and what this means for accelerated drug approval:
buff.ly/jCeKyZp
September 19, 2025 at 8:30 PM
Attending the #IMS25 Regulatory Session?
Check out this review article on how MRD received FDA approval as an early endpoint for myeloma and what this means for accelerated drug approval:
buff.ly/jCeKyZp
Check out this review article on how MRD received FDA approval as an early endpoint for myeloma and what this means for accelerated drug approval:
buff.ly/jCeKyZp
Reposted
Paola Neri presents data from her recent Blood Cancer Discovery paper, "Timing genomic antigen loss in multiple myeloma treated with T-cell redirecting immunotherapies" at #IMS25.
Read the article: buff.ly/vlQra5A
Read the article: buff.ly/vlQra5A
September 21, 2025 at 3:22 PM
Paola Neri presents data from her recent Blood Cancer Discovery paper, "Timing genomic antigen loss in multiple myeloma treated with T-cell redirecting immunotherapies" at #IMS25.
Read the article: buff.ly/vlQra5A
Read the article: buff.ly/vlQra5A
Reposted
another illustrative study of "one-size-fits all" prognostic stratification in acute leukemia doesn't always work! The prognostic value of gene mutations commonly thought to impact risk in African-ancestry patients with T-ALL was limited!
aacrjournals.org/bloodcancerd...
aacrjournals.org/bloodcancerd...
June 4, 2025 at 4:59 PM
another illustrative study of "one-size-fits all" prognostic stratification in acute leukemia doesn't always work! The prognostic value of gene mutations commonly thought to impact risk in African-ancestry patients with T-ALL was limited!
aacrjournals.org/bloodcancerd...
aacrjournals.org/bloodcancerd...
an excellent article looking at various subtypes of myeloid malignancies!
-SF3B1 VAF matters for MDS subtypes
-blast % doesn't matter for NPM1m; HR mutations impact outcome in NPM1m AML
-molecular data helps to separate oligomonocytic CMML from MDS
aacrjournals.org/bloodcancerd...
-SF3B1 VAF matters for MDS subtypes
-blast % doesn't matter for NPM1m; HR mutations impact outcome in NPM1m AML
-molecular data helps to separate oligomonocytic CMML from MDS
aacrjournals.org/bloodcancerd...
September 16, 2025 at 3:23 PM
Reposted
Louis M. Staudt, M.D., Ph.D., has pioneered molecular classification of cancers, specifically lymphomas. Speaking with Blood Cancer Discovery’s Abigail Cleveland, Dr. Staudt shares his career experience on the path to scientific discovery. Read the Q&A:
buff.ly
July 1, 2025 at 6:54 PM
Louis M. Staudt, M.D., Ph.D., has pioneered molecular classification of cancers, specifically lymphomas. Speaking with Blood Cancer Discovery’s Abigail Cleveland, Dr. Staudt shares his career experience on the path to scientific discovery. Read the Q&A:
Reposted
In this recent Blood Cancer Discovery article by @morinryan.bsky.social, DNA methylation profiling reveals two BL epitypes with distinct molecular and clinical features, offering a new framework for understanding BL pathogenesis.
Read the study: buff.ly/PGqUMvz
Read the study: buff.ly/PGqUMvz
July 9, 2025 at 4:19 PM
In this recent Blood Cancer Discovery article by @morinryan.bsky.social, DNA methylation profiling reveals two BL epitypes with distinct molecular and clinical features, offering a new framework for understanding BL pathogenesis.
Read the study: buff.ly/PGqUMvz
Read the study: buff.ly/PGqUMvz
Reposted
AACR Journals in the news: buff.ly/1p578T3
In this Blood Cancer Discovery study, Teclistamab-cqyv led to clinically meaningful responses in patients with heavily pretreated multiple myeloma who would have been ineligible for the MajesTEC-1 trial. Check it out: buff.ly/wMmq7EK
In this Blood Cancer Discovery study, Teclistamab-cqyv led to clinically meaningful responses in patients with heavily pretreated multiple myeloma who would have been ineligible for the MajesTEC-1 trial. Check it out: buff.ly/wMmq7EK
July 12, 2025 at 3:26 PM
AACR Journals in the news: buff.ly/1p578T3
In this Blood Cancer Discovery study, Teclistamab-cqyv led to clinically meaningful responses in patients with heavily pretreated multiple myeloma who would have been ineligible for the MajesTEC-1 trial. Check it out: buff.ly/wMmq7EK
In this Blood Cancer Discovery study, Teclistamab-cqyv led to clinically meaningful responses in patients with heavily pretreated multiple myeloma who would have been ineligible for the MajesTEC-1 trial. Check it out: buff.ly/wMmq7EK
Reposted
Read this collection of impactful Blood Cancer Discovery articles that highlight advanced lymphoma research by leveraging novel tools and techniques, uncovering molecular networks that drive oncogenesis and progression, and bringing innovative therapies to patients. buff.ly/q3NmZc2
August 26, 2025 at 10:07 PM
Read this collection of impactful Blood Cancer Discovery articles that highlight advanced lymphoma research by leveraging novel tools and techniques, uncovering molecular networks that drive oncogenesis and progression, and bringing innovative therapies to patients. buff.ly/q3NmZc2
Reposted
Congratulations to Courtney D. DiNardo, MD, MSCE, and colleagues, recipients of the 2025 Blood Cancer Discovery Award for Outstanding Journal Article. Learn more and read the article: buff.ly/43MI9n0
August 27, 2025 at 4:06 PM
Congratulations to Courtney D. DiNardo, MD, MSCE, and colleagues, recipients of the 2025 Blood Cancer Discovery Award for Outstanding Journal Article. Learn more and read the article: buff.ly/43MI9n0
Real-World Experience with Teclistamab for Relapsed/ Refractory Multiple Myeloma ft. Beatrice Razzo, Sandra Susanibar-Adaniya, Alfred Garfall (@penncancer.bsky.social), Wei-Ting Hwang (@dbei-upenn.bsky.social) & Anna Chen (@pennmedicine.bsky.social) aacrjournals.org/bloodcancerd...
August 18, 2025 at 12:53 PM
Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
doi.org/10.1158/2643...
doi.org/10.1158/2643...
August 18, 2025 at 12:28 PM
Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
doi.org/10.1158/2643...
doi.org/10.1158/2643...
1,157 people with TP53-CHIP from BioBankJapan followed over a decade (vs 140,000 controls), TP53-CHIP associated with myeloid, lymphoid neoplasms, respiratory disease mortality. The impact is modulated by lifestyle (smoking and drinking). Stay healthy!
#clonalhematopoiesis
doi.org/10.1158/2643...
#clonalhematopoiesis
doi.org/10.1158/2643...
August 18, 2025 at 12:13 PM
1,157 people with TP53-CHIP from BioBankJapan followed over a decade (vs 140,000 controls), TP53-CHIP associated with myeloid, lymphoid neoplasms, respiratory disease mortality. The impact is modulated by lifestyle (smoking and drinking). Stay healthy!
#clonalhematopoiesis
doi.org/10.1158/2643...
#clonalhematopoiesis
doi.org/10.1158/2643...
Now online @BCD_AACR: Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
#MMsm #CARTcell #microbiome #immunotherapy
aacrjournals.org/bloodcancerd...
#MMsm #CARTcell #microbiome #immunotherapy
aacrjournals.org/bloodcancerd...
August 18, 2025 at 12:04 PM
Now online @BCD_AACR: Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
#MMsm #CARTcell #microbiome #immunotherapy
aacrjournals.org/bloodcancerd...
#MMsm #CARTcell #microbiome #immunotherapy
aacrjournals.org/bloodcancerd...
Reposted
Check out our new 'In Focus' article on overcoming B-cell acute lymphoblastic leukemia resistance by combining targeted and immune therapies in Blood Cancer Discovery! Big shoutout to Miguel and Grace for their fantastic work. t.co/bBuHxhKgCf
April 28, 2025 at 1:09 PM
Check out our new 'In Focus' article on overcoming B-cell acute lymphoblastic leukemia resistance by combining targeted and immune therapies in Blood Cancer Discovery! Big shoutout to Miguel and Grace for their fantastic work. t.co/bBuHxhKgCf
Reposted
I am so excited to share that our new paper is out!
A model of intratumor and interpatient heterogeneity explains clinical trials of curative combination therapy for lymphoma
Out in Blood Cancer Discovery
doi.org/10.1158/2643-3230.BCD-24-0230
#mathonc #lymsm #BloodCancer
1/n
A model of intratumor and interpatient heterogeneity explains clinical trials of curative combination therapy for lymphoma
Out in Blood Cancer Discovery
doi.org/10.1158/2643-3230.BCD-24-0230
#mathonc #lymsm #BloodCancer
1/n
A model of intra-tumor and inter-patient heterogeneity explains clinical trials of curative combination therapy for lymphoma
Abstract. Models of tumor drug response have illuminated important concepts in oncology, but there remains a need for theory that combines intra-tumor and inter-patient heterogeneity to explain patien...
doi.org
April 10, 2025 at 3:57 PM
I am so excited to share that our new paper is out!
A model of intratumor and interpatient heterogeneity explains clinical trials of curative combination therapy for lymphoma
Out in Blood Cancer Discovery
doi.org/10.1158/2643-3230.BCD-24-0230
#mathonc #lymsm #BloodCancer
1/n
A model of intratumor and interpatient heterogeneity explains clinical trials of curative combination therapy for lymphoma
Out in Blood Cancer Discovery
doi.org/10.1158/2643-3230.BCD-24-0230
#mathonc #lymsm #BloodCancer
1/n
Reposted
Cures in Crisis: Senators Baldwin and Welch hosted a forum featuring researchers, patients, and former NIH Director Monica Bertagnolli, MD, discussing the impact of recent NIH disruptions on scientific progress and patient care. Watch the recap: www.youtube.com/live/JofqSdW...
@baldwin.senate.gov
@baldwin.senate.gov
March 26, 2025 at 9:05 PM
Cures in Crisis: Senators Baldwin and Welch hosted a forum featuring researchers, patients, and former NIH Director Monica Bertagnolli, MD, discussing the impact of recent NIH disruptions on scientific progress and patient care. Watch the recap: www.youtube.com/live/JofqSdW...
@baldwin.senate.gov
@baldwin.senate.gov
Reposted
Happy to share our In Focus comment on targeting metabolism in T-ALL in #BloodCancerDiscovery, single-handedly written by @dasilva-diz.bsky.social! Thanks for the invitation to write on such an exciting topic @tanyabondar.bsky.social! @rutgerscancer.bsky.social aacrjournals.org/bloodcancerd...
March 21, 2025 at 3:49 PM
Happy to share our In Focus comment on targeting metabolism in T-ALL in #BloodCancerDiscovery, single-handedly written by @dasilva-diz.bsky.social! Thanks for the invitation to write on such an exciting topic @tanyabondar.bsky.social! @rutgerscancer.bsky.social aacrjournals.org/bloodcancerd...
Trees don't have p53,
yet are cancer-free.
No malignancies, despite
huge exposures to sunlight.
Can we learn from a tree
how to stay cancer-free?
yet are cancer-free.
No malignancies, despite
huge exposures to sunlight.
Can we learn from a tree
how to stay cancer-free?
March 20, 2025 at 4:32 PM
Trees don't have p53,
yet are cancer-free.
No malignancies, despite
huge exposures to sunlight.
Can we learn from a tree
how to stay cancer-free?
yet are cancer-free.
No malignancies, despite
huge exposures to sunlight.
Can we learn from a tree
how to stay cancer-free?
And as this is a relapse, it is spreading and damaging vital organs at a much faster pace that the first occurrence. It also appears resistant to conventional treatments.
March 12, 2025 at 4:29 PM
And as this is a relapse, it is spreading and damaging vital organs at a much faster pace that the first occurrence. It also appears resistant to conventional treatments.
Reposted
GLP-1 drugs association with reduced risk of blood cancers (leukemias and lymphomas)
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
March 6, 2025 at 5:15 PM
GLP-1 drugs association with reduced risk of blood cancers (leukemias and lymphomas)
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
Reposted
Not enough to cut funding. Now a list of over 20 health and life science topics that cannot be published by National Cancer Institute scientists without "oversight" (i.e. censorship).
NEW: Vaccines. Fluoride. Autism.
Communications involving these and 20 other “controversial, high profile, or sensitive” topics will get extra scrutiny under Health Secretary Robert F. Kennedy Jr.
By @anniewaldman.bsky.social and @lisalsong.bsky.social
Communications involving these and 20 other “controversial, high profile, or sensitive” topics will get extra scrutiny under Health Secretary Robert F. Kennedy Jr.
By @anniewaldman.bsky.social and @lisalsong.bsky.social
National Cancer Institute Employees Can’t Publish Information on These Topics Without Special Approval
Vaccines. Fluoride. Autism. Communications involving these and 20 other “controversial, high profile, or sensitive” topics will get extra scrutiny under Health Secretary Robert F. Kennedy Jr.
propub.li
March 10, 2025 at 5:51 PM
Not enough to cut funding. Now a list of over 20 health and life science topics that cannot be published by National Cancer Institute scientists without "oversight" (i.e. censorship).
Reposted
If our "academic leaders" are wondering what a real leader looks like, look no further. Who will follow Dr. Varmus?
www.nytimes.com/2025/02/14/o...
www.nytimes.com/2025/02/14/o...
Opinion | American Science is Under Attack (Gift Article)
The Trump administration hobbles research and endangers the public health.
www.nytimes.com
February 15, 2025 at 1:59 AM
If our "academic leaders" are wondering what a real leader looks like, look no further. Who will follow Dr. Varmus?
www.nytimes.com/2025/02/14/o...
www.nytimes.com/2025/02/14/o...
Reposted
Hematologists & pathologists find these cells fascinating: ring sideroblasts.
While most commonly associated with #MDS or inherited genetic disorders like #XLSA or #MLASA, these cells can also result from ethanol or tuberculosis drugs - even hypothermia.
They have such an interesting history!/1
While most commonly associated with #MDS or inherited genetic disorders like #XLSA or #MLASA, these cells can also result from ethanol or tuberculosis drugs - even hypothermia.
They have such an interesting history!/1
November 22, 2024 at 9:38 PM